What Melatonin Is and Why Researchers Are Studying It for Glioblastoma
Melatonin is a hormone made by the pineal gland, a small structure deep in the brain. Your body releases it at night to signal that it's time to sleep. Most people know it as a natural sleep aid. But melatonin also works as an antioxidant, reduces inflammation, and has caught the attention of cancer researchers. This is especially true for those studying glioblastoma (GBM), the most aggressive primary brain tumor in adults.
Melatonin is made in the brain and crosses the blood-brain barrier easily. This means it can reach tumor tissue in ways many lab-made compounds cannot. Because of this advantage and early lab findings showing it may fight tumors, scientists are studying whether melatonin could help alongside standard GBM treatment. Standard treatment includes surgery, radiation, and temozolomide (TMZ) chemotherapy.
This article explains what science currently shows, what questions still need answers, and what to discuss with your care team if you're thinking about melatonin as part of your treatment plan. This article doesn't recommend specific doses or plans. Talk with your neuro-oncologist about those details.
How Melatonin May Act Against Glioblastoma Cells
Pre-clinical research (lab and animal studies) has found several ways melatonin may slow glioblastoma growth or make tumor cells easier to treat. A review published in the journal Biomolecules outlined the main ways researchers have seen melatonin fight GBM in lab models:
- Triggering apoptosis (programmed cell death): Melatonin appears to activate death signals inside GBM cells, including pathways involving caspase-3 and the tumor suppressor protein p53. In lab studies, this can slow or stop tumor cell growth.
- Reducing cell invasion and migration: GBM spreads by invading healthy brain tissue. Several studies suggest melatonin may reduce how well GBM cells move through surrounding tissue. This partly explains why the tumor is so difficult to control after surgery.
- Anti-angiogenic effects: GBM builds new blood vessels to feed its rapid growth, a process called angiogenesis. Melatonin may interfere with some of the chemical signals that drive this process, limiting the tumor's access to nutrients. For more on how GBM hijacks the brain's blood supply, see our article on angiogenesis and blood-brain barrier disruption in glioblastoma.
- Antioxidant and anti-inflammatory effects: GBM creates an inflammatory environment that can fuel tumor growth. Melatonin's ability to reduce oxidative stress may dampen certain pro-tumor inflammatory signals.
- Disrupting tumor metabolism: A study published in the journal Cancers found that melatonin triggered a metabolic imbalance inside GBM cells. Specifically, it disrupted the cell's internal pH in ways that interfered with how tumor cells produce energy.
These findings come mainly from cell cultures and animal models. They provide a reason for further research but do not prove the same effects happen in human patients taking over-the-counter doses.
Melatonin and Temozolomide: A Potential Synergy
The most clinically relevant area of melatonin research in GBM may be its potential to work with temozolomide. Temozolomide is the chemotherapy drug central to the standard Stupp protocol for newly diagnosed GBM. TMZ works by damaging the DNA of rapidly dividing tumor cells, but two major problems limit its effectiveness: drug resistance (closely linked to MGMT promoter methylation status) and toxicity to healthy tissue. To understand how MGMT status shapes temozolomide response, our article on MGMT methylation and temozolomide response in glioblastoma explains the biology in detail.
A 2025 study published in the Journal of Cellular and Molecular Medicine examined what happens when melatonin and TMZ are combined in GBM cell lines. The researchers found that the combination increased tumor cell death compared to TMZ alone. The mechanism involved melatonin blocking the NF-kB/COX-2 signaling pathway. GBM cells commonly use this pathway to resist chemotherapy and promote their own survival. By blocking this pathway, melatonin appeared to make GBM cells more sensitive to TMZ's DNA-damaging effects and triggered cell death through caspase-3 activation.
A separate pre-clinical study found that melatonin enhanced TMZ-induced cell death in GBM cells by increasing caspase-3 activity and the pro-apoptotic protein Bax, while reducing Bcl-2. Bcl-2 is a protein that helps cancer cells escape programmed death. That study, indexed on PubMed, also reported cell cycle arrest as part of the combination's effect. This suggests melatonin may slow tumor cell replication while preparing cells to respond to chemotherapy.
Some researchers have proposed that combining melatonin with TMZ might eventually allow lower chemotherapy doses. Lower doses could mean fewer side effects. This hypothesis has not yet been confirmed in large human trials, but it is one reason scientists are pursuing formal study of this combination.
Overcoming TMZ Resistance: An Emerging Line of Inquiry
One of the most frustrating realities of GBM treatment is that most tumors eventually develop resistance to temozolomide. This resistance can involve multiple mechanisms: DNA repair enzymes (most notably the MGMT protein), glioma stem cells, and drug efflux pumps that actively push chemotherapy out of tumor cells before it can cause damage.
Early research suggests melatonin may address some of these resistance pathways. One study found that melatonin affected the methylation of the ABCG2/BCRP promoter in brain tumor stem cells. This gene is tied to drug efflux activity. The change potentially made those cells more vulnerable to chemotherapy. This is a highly experimental finding that has not been replicated in clinical settings, but it points to a possible reason the combination may warrant formal clinical study.
A narrative review of melatonin's effects on GBM, accessible through PubMed Central, summarized the current state of knowledge this way: despite pre-clinical evidence, clinical data in GBM-specific patient populations remain limited. The authors called for well-designed human trials to determine whether laboratory findings translate into meaningful patient benefit.
Reducing Chemotherapy Side Effects: Signals from the Broader Cancer Literature
While GBM-specific clinical trial data on melatonin is limited, a broader body of cancer research examines melatonin's potential to reduce the side effects of chemotherapy and radiation. Much of this evidence comes from breast cancer populations, but the underlying biology is relevant to GBM patients managing TMZ-related toxicities.
A review published in the journal Aging and Disease found evidence suggesting melatonin may help counteract several types of chemotherapy-related harm:
- Myelosuppression (bone marrow suppression): TMZ can lower white blood cell and platelet counts, raising infection and bleeding risk. Some studies suggest melatonin may protect bone marrow cells, though this evidence is largely pre-clinical in the GBM context.
- Neurotoxicity: Both TMZ and cranial radiation can affect healthy brain tissue over time. Melatonin's antioxidant and neuroprotective properties may reduce this collateral damage. However, most supporting data come from animal models rather than GBM-specific human trials.
- Fatigue: Cancer-related fatigue is one of the most debilitating side effects of GBM treatment. Several randomized trials in breast cancer patients suggest melatonin may modestly reduce treatment-related fatigue. However, results vary across studies, and GBM-specific fatigue data remain limited.
- Nausea and gastrointestinal symptoms: Melatonin may reduce TMZ-related nausea and appetite loss in some patients. However, it can also cause mild nausea itself at higher doses in some people.
An important caveat: these findings come mainly from non-GBM cancer populations. The immune environment, blood-brain barrier dynamics, and the specific drugs and radiation doses used in GBM care differ meaningfully from other cancers. Your neuro-oncologist is the right person to evaluate whether these findings apply to your specific situation.
Sleep Quality, Circadian Rhythm, and GBM Treatment
Beyond its direct anti-tumor effects, melatonin's role in sleep regulation deserves attention in the GBM context. Sleep disruption is very common during brain tumor treatment. Corticosteroids like dexamethasone, anxiety, anti-seizure medications, and the tumor itself can disrupt sleep. Poor sleep worsens fatigue, immune function, mood, and overall quality of life during treatment.
Disrupted circadian rhythms (the body's internal clock, which melatonin helps regulate) have been associated with worse outcomes in several cancer types. However, the relationship has not yet been deeply studied in GBM specifically. Some researchers hypothesize that normalizing circadian signaling during treatment may support immune function and improve the body's ability to respond to therapy. This remains an area of active hypothesis in cancer biology rather than an established clinical strategy for brain tumors.
For patients experiencing corticosteroid-related insomnia or treatment-disrupted sleep, melatonin is frequently raised in integrative oncology discussions as a low-risk option. However, always coordinate its use with your care team. It can interact with other medications and requires careful timing relative to certain therapies. For a broader look at complementary approaches used alongside standard GBM care, see our overview of integrative treatments for glioblastoma.
What the Clinical Trial Landscape Looks Like
As of early 2024, a systematic review of registered trials on ClinicalTrials.gov identified 46 clinical trials examining melatonin in cancer treatment. Of these, 24 had been completed and 5 were actively recruiting. However, GBM-specific trials remain rare. Most registered melatonin trials have focused on breast, lung, and other cancers. The authors noted that melatonin research in brain tumors is an area that needs more attention despite strong pre-clinical evidence.
This matters for patients and families. While the laboratory science is encouraging, the kind of human evidence needed to support clinical recommendations does not yet exist. Large randomized controlled trials in GBM patients are still needed. Any patient considering melatonin as part of their treatment support plan should understand this distinction: the pre-clinical science is promising, but clinical validation in GBM is still in its early stages.
Patients interested in finding active studies may search ClinicalTrials.gov using the terms melatonin and glioblastoma to identify any currently recruiting trials. Discussing trial eligibility with your neuro-oncologist is the most reliable way to evaluate your options.
Safety Profile and Drug Interaction Considerations
Melatonin has a well-established short-term safety record at standard supplement doses. Clinical trials in cancer patients consistently report only mild, transient side effects: headache, daytime drowsiness, and occasional nausea. No severe adverse events have been consistently documented in cancer-related melatonin trials at the doses studied.
However, several interactions are worth discussing with your care team before adding melatonin:
- Melatonin may interact with corticosteroids like dexamethasone, which are frequently used in GBM to control brain swelling.
- It has mild blood-thinning properties, which matters for patients on anticoagulants.
- Melatonin can affect the metabolism of certain drugs processed by the liver's cytochrome P450 enzyme system. The same system processes many chemotherapy agents and anti-seizure medications commonly prescribed in brain tumor care.
- High-dose melatonin protocols appear in some research studies but should not be self-prescribed. Research doses differ substantially from standard over-the-counter products, and higher doses carry different risks.
The Memorial Sloan Kettering Cancer Center's integrative medicine database, available at mskcc.org, provides a regularly updated summary of melatonin's known drug interactions and clinical evidence. This is a useful resource for patients and caregivers reviewing this topic alongside their care team.
The Bottom Line: Promising Science, Limited Human Trials
Melatonin has an interesting position in the GBM research landscape. The laboratory evidence is substantial: multiple peer-reviewed studies suggest it may make GBM cells more sensitive to temozolomide, reduce tumor cell migration, disrupt tumor metabolism, and provide neuroprotective effects during treatment. Its natural ability to cross the blood-brain barrier gives it an advantage over many compounds being studied for brain tumor applications.
At the same time, the gap between laboratory promise and clinical proof is significant. GBM-specific human trials are limited. Dosages, timing, and formulations vary considerably across studies. Melatonin, like any bioactive compound, carries interaction risks that depend on each patient's full medication list, tumor characteristics, and treatment schedule.
For GBM patients and families exploring every possible supportive strategy, melatonin may be worth a focused, evidence-informed conversation with your care team. This is especially true around sleep quality, chemotherapy tolerance, and quality of life. It should not replace standard-of-care treatment. Do not add any supplement to a GBM protocol without direct oncologist input.
When to Talk to Your Doctor
Bring up melatonin with your neuro-oncologist or integrative oncology team if you are experiencing significant sleep disruption during treatment, struggling with treatment-related fatigue, or exploring strategies to complement your standard-of-care plan. Ask specifically about interactions with your current medications, particularly dexamethasone, anti-seizure drugs, and temozolomide. Also ask whether the timing of supplement use matters for your specific protocol.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.